{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T12:28:10Z","timestamp":1648902490417},"reference-count":69,"publisher":"FapUNIFESP (SciELO)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq Bras Endocrinol Metab"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:p>A acromegalia acarreta uma s\u00e9rie de dist\u00farbios ao sistema cardiovascular, decorrentes da exposi\u00e7\u00e3o cr\u00f4nica a n\u00edveis elevados de GH e IGF-1. Estes dist\u00farbios s\u00e3o os principais respons\u00e1veis pelo aumento da mortalidade de acromeg\u00e1licos. Entre as v\u00e1rias formas de acometimento cardiovascular, destaca-se a miocardiopatia acromeg\u00e1lica, entidade caracterizada, inicialmente, pelo estado hiperdin\u00e2mico, seguido de hipertrofia ventricular esquerda conc\u00eantrica e disfun\u00e7\u00e3o diast\u00f3lica por d\u00e9ficit de relaxamento, culminando com disfun\u00e7\u00e3o sist\u00f3lica e, por vezes, insufici\u00eancia card\u00edaca franca. Al\u00e9m disso, s\u00e3o tamb\u00e9m relevantes as arritmias, as valvulopatias, sobretudo mitral e a\u00f3rtica, a cardiopatia isqu\u00eamica, a hipertens\u00e3o e os dist\u00farbios dos metabolismos glic\u00eamico e lip\u00eddico. Nesta revis\u00e3o s\u00e3o abordados os principais aspectos cl\u00ednicos e progn\u00f3sticos destas entidades, os efeitos do tratamento da acromegalia sobre elas e as repercuss\u00f5es correspondentes sobre a sobrevida dos pacientes.<\/jats:p>","DOI":"10.1590\/s0004-27302008000900004","type":"journal-article","created":{"date-parts":[[2009,2,4]],"date-time":"2009-02-04T12:18:46Z","timestamp":1233749926000},"page":"1416-1429","source":"Crossref","is-referenced-by-count":10,"title":["Dist\u00farbios cardiovasculares na acromegalia"],"prefix":"10.1590","volume":"52","author":[{"given":"Daniela","family":"Fedrizzi","sequence":"first","affiliation":[{"name":"Hospital de Cl\u00ednicas de Porto Alegre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mauro Antonio","family":"Czepielewski","sequence":"additional","affiliation":[{"name":"Universidade Federal do Rio Grande do Sul, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"1","key":"ref1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1023\/A:1009965803750","article-title":"Epidemiology of acromegaly","volume":"2","author":"Holdaway IM","year":"1999","journal-title":"Pituitary","ISSN":"http:\/\/id.crossref.org\/issn\/1386-341X","issn-type":"print"},{"key":"ref2","series-title":"The Pituitary","first-page":"419","volume-title":"Acromegaly","author":"Melmed S.","year":"2002"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1210\/er.2002-0022","article-title":"Systemic complications of acromegaly: epidemiology, pathogenesis, and management","volume":"25","author":"Colao A","year":"2004","journal-title":"Endocr Rev."},{"issue":"24","key":"ref4","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1056\/NEJMra062453","article-title":"Medical progress: acromegaly","volume":"355","author":"Melmed S","year":"2006","journal-title":"N Engl J Med."},{"key":"ref5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2165\/00024677-200403050-00004","article-title":"Cardiac abnormalities in acromegaly: Pathophysiology and implications for management","volume":"3(5)","author":"Vitale G","year":"2004","journal-title":"Treat Endocrinol."},{"issue":"3","key":"ref6","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1210\/er.2003-0009","article-title":"Cardiovascular function in acromegaly","volume":"24","author":"Clayton RN","year":"2003","journal-title":"Endocr Rev."},{"issue":"6","key":"ref7","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1046\/j.1365-2265.2001.01281.x","article-title":"Characterization of premature atherosclerosis of carotid arteries in acromegalic patients","volume":"54","author":"Otsuki M","year":"2001","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"4","key":"ref8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/MED.0b013e32816e06cc","article-title":"Current thinking on the management of the acromegalic patient","volume":"14","author":"Katznelson L","year":"2007","journal-title":"Curr Opin Endocrinol Diabetes Obes."},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1530\/eje.0.1510439","article-title":"Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly based on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA)","volume":"151","author":"Mestron A","year":"2004","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"ref10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway IM","year":"2004","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers OM","year":"2008","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"4","key":"ref12","first-page":"511","article-title":"Growth hormone (GH) and IGF-I assays: methodological aspects and its implications in acromegaly diagnosis and follow-up","volume":"51","author":"Casagrande A","year":"2007","journal-title":"Arq Bras Endocrinol Metabol."},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2265.1998.00493.x","article-title":"Echocardiographic evidence for a direct effect of GH\/IGF-I hypersecretion on cardiac mass and function in young acromegalics","volume":"49","author":"Minniti G","year":"1998","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"ref14","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2265.2001.01218.x","article-title":"Growth hormone and the heart","volume":"54","author":"Colao A","year":"2001","journal-title":"Clinical Endocrinology."},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1210\/edrv-15-5-555","article-title":"Growth hormone and the heart","volume":"15","author":"Sacca L","year":"1994","journal-title":"Endocr Rev."},{"issue":"3","key":"ref16","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1365-2265.2004.01985.x","article-title":"Prevalence and determinants of left ventricular hypertrophy in acromegaly: impact of different methods of indexing left ventricular mass","volume":"60","author":"Vitale G","year":"2004","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1210\/jcem.85.1.6313","article-title":"Cardiovascular effects of short-term growth hormone hypersecretion","volume":"85","author":"Fazio S","year":"2000","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"1","key":"ref18","first-page":"82","article-title":"Cardiac morphology and performance alterations and analysis of determinant factors of left ventricular hypertrophy in 40 patients with acromegaly","volume":"50","author":"Casini AF","year":"2006","journal-title":"Arq Bras Endocrinol Metabol."},{"issue":"4","key":"ref19","first-page":"1047","article-title":"Cardiac involvement in acromegaly: specific myocardiopathy or consequence of systemic hypertension?","volume":"82","author":"Lopez-Velasco R","year":"1997","journal-title":"J Clin Endocrinol Metabolism"},{"issue":"10","key":"ref20","first-page":"3419","article-title":"Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly","volume":"83","author":"Swearingen B","year":"1998","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"1","key":"ref21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1530\/acta.0.1080026","article-title":"Progression of cardiovascular disease in acromegalic patients treated by external pituitary irradiation","volume":"108","author":"Baldwin A","year":"1985","journal-title":"Acta Endocrinol (Copenh)."},{"issue":"4","key":"ref22","first-page":"1551","article-title":"Is the acromegalic cardiomyopathy reversible?: Effect of 5-year normalization of growth hormone and insulin-like growth factor I levels on cardiac performance","volume":"86","author":"Colao A","year":"2001","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2265.2001.01343.x","article-title":"Marked improvement in cardiovascular function after successful transsphenoidal surgery in acromegalic patients","volume":"55","author":"Minniti G","year":"2001","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/eje.0.1510179","article-title":"Evaluation of cardiac structure by echoreflectivity analysis in acromegaly: effects of treatment","volume":"151","author":"Ciulla MM","year":"2004","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"ref25","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1046\/j.1365-2265.2003.01689.x","article-title":"Reversal of acromegalic cardiomyopathy in young but not in middle-aged patients after 12 months of treatment with the depot long-acting somatostatin analogue octreotide","volume":"58","author":"Colao A","year":"2003","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"ref26","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1210\/jc.2006-2547","article-title":"Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis","volume":"92","author":"Maison P","year":"2007","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1210\/jc.2006-1587","article-title":"Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance","volume":"92","author":"Pivonello R","year":"2007","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/oxfordjournals.eurheartj.a060047","article-title":"Arrhythmia profile in acromegaly","volume":"13","author":"Kahaly G","year":"1992","journal-title":"Eur Heart J."},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1111\/j.1365-2265.2006.02639.x","article-title":"Effects of treatment with somatostatin analogues on QT interval duration in acromegalic patients","volume":"65","author":"Fatti LM","year":"2006","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1365-2265.2001.01319.x","article-title":"Occurrence of ventricular late potentials in patients with active acromegaly","volume":"55","author":"Herrmann BL","year":"2001","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"11","key":"ref31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/BF03344070","article-title":"Improvement of left ventricular hypertrophy and arrhythmias after lanreotide-induced GH and IGF-I decrease in acromegaly: A prospective multi-center study","volume":"25","author":"Lombardi G","year":"2002","journal-title":"J Endocrinol Invest."},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"3196","DOI":"10.1210\/jc.2002-021099","article-title":"High prevalence of cardiac valve disease in acromegaly: an observational, analytical, case-control study","volume":"88","author":"Colao A","year":"2003","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-8703(80)90277-X","article-title":"Pathology of the heart in acromegaly: anatomic findings in 27 autopsied patients","volume":"100","author":"Lie JT","year":"1980","journal-title":"Am Heart J."},{"issue":"2","key":"ref34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0003-4975(97)00788-1","article-title":"Heart valve operation in acromegaly","volume":"64","author":"Ohtsuka G","year":"1997","journal-title":"Ann Thorac Surg."},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1210\/jc.2003-030849","article-title":"Increased prevalence of regurgitant valvular heart disease in acromegaly","volume":"89","author":"Pereira AM","year":"2004","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"2","key":"ref36","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ghir.2006.02.002","article-title":"Uncontrolled acromegaly is associated with progressive mitral valvular regurgitation","volume":"16","author":"van der Klaauw AA","year":"2006","journal-title":"Growth Horm IGF Res"},{"issue":"1","key":"ref37","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini R","year":"2007","journal-title":"N Engl J Med."},{"issue":"1","key":"ref38","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJMoa062222","article-title":"Dopamine agonists and the risk of cardiac-valve regurgitation","volume":"356","author":"Schade R","year":"2007","journal-title":"N Engl J Med."},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","article-title":"Atherosclerosis-an inflammatory disease","volume":"340","author":"Ross R","year":"1999","journal-title":"New England Journal of Medicine."},{"issue":"6","key":"ref40","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1046\/j.1365-2265.1998.00620.x","article-title":"Decreased regional blood flow in patients with acromegaly","volume":"49","author":"Chanson P","year":"1998","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"4","key":"ref41","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1046\/j.1365-2265.2000.01127.x","article-title":"Vascular reactivity in acromegalic patients: preliminary evidence for regional endothelial dysfunction and increased sympathetic vasoconstriction","volume":"53","author":"Maison P","year":"2000","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7","key":"ref42","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1210\/jcem.87.7.8643","article-title":"Early vascular alterations in acromegaly","volume":"87","author":"Brevetti G","year":"2002","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"9","key":"ref43","first-page":"3151","article-title":"Morphologic study of microcirculation in acromegaly by capillaroscopy","volume":"84","author":"Schiavon F","year":"1999","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"4","key":"ref44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1365-2265.2001.01256.x","article-title":"Increased arterial intima-media thickness by B-M mode echodoppler ultrasonography in acromegaly","volume":"54","author":"Colao A","year":"2001","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"7","key":"ref45","doi-asserted-by":"crossref","first-page":"4081","DOI":"10.1210\/jc.2004-1381","article-title":"A nationwide survey of mortality in acromegaly","volume":"90","author":"Kauppinen-Makelin R","year":"2005","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"10","key":"ref46","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1210\/jc.2005-2857","article-title":"Acromegaly and coronary disease: an integrated evaluation of conventional coronary risk factors and coronary calcifications detected by computed tomography","volume":"91","author":"Cannavo S","year":"2006","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"11","key":"ref47","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1210\/jc.2007-1213","article-title":"Risk factors for development of coronary heart disease in patients with acromegaly: a five-year prospective study","volume":"92","author":"Bogazzi F","year":"2007","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"4","key":"ref48","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1365-2265.2005.02370.x","article-title":"Hypertension in acromegaly and in the normal population: prevalence and determinants","volume":"63","author":"Vitale G","year":"2005","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"12","key":"ref49","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1210\/jc.2006-0049","article-title":"CYP11B2-344T\/C gene polymorphism and blood pressure in patients with acromegaly","volume":"91","author":"Mulatero P","year":"2006","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"5","key":"ref50","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2265.2007.02782.x","article-title":"N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances","volume":"66","author":"Andreassen M","year":"2007","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"6","key":"ref51","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1210\/jc.2002-021746","article-title":"The effects of depot long-acting somatostatin analog on central aortic pressure and arterial stiffness in acromegaly","volume":"88","author":"Smith JC","year":"2003","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"3","key":"ref52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1161\/01.HYP.0000114604.52270.95","article-title":"Acromegalic patients show the presence of hypertrophic remodeling of subcutaneous small resistance arteries","volume":"43","author":"Rizzoni D","year":"2004","journal-title":"Hypertension","ISSN":"http:\/\/id.crossref.org\/issn\/0194-911X","issn-type":"print"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1530\/eje.0.1420179","article-title":"Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion","volume":"142","author":"Rio GD","year":"2000","journal-title":"Eur J Endocrinol."},{"issue":"7","key":"ref54","first-page":"2458","article-title":"Diurnal rhythm of plasma catecholamines in acromegaly","volume":"84","author":"Bondanelli M","year":"1999","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"2","key":"ref55","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1046\/j.1365-2265.2001.01206.x","article-title":"Relationship between blood pressure and glucose tolerance in acromegaly","volume":"54","author":"Jaffrain-Rea ML","year":"2001","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"5","key":"ref56","first-page":"423","article-title":"Growth hormone, the insulin-like growth factor system, and the kidney","volume":"17","author":"Feld S","year":"1996","journal-title":"Endocr Rev."},{"issue":"1","key":"ref57","first-page":"193","article-title":"Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy","volume":"85","author":"Colao A","year":"2000","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"1","key":"ref58","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2005-1704","article-title":"Comparison between six-year therapy with long-acting somatostatin analogs and successful surgery in acromegaly: effects on cardiovascular risk factors","volume":"91","author":"Ronchi CL","year":"2006","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"6","key":"ref59","doi-asserted-by":"crossref","first-page":"537","DOI":"10.7326\/0003-4819-130-6-199903160-00021","article-title":"Lipoprotein(a) in acromegaly","volume":"130","author":"Maffei P","year":"1999","journal-title":"Ann Intern Med."},{"issue":"3","key":"ref60","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1046\/j.1365-2265.2000.01092.x","article-title":"Effects of normalization of GH hypersecretion on lipoprotein(a) and other lipoprotein serum levels in acromegaly","volume":"53","author":"Maldonado Castro GF","year":"2000","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"4","key":"ref61","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4158\/EP.13.4.363","article-title":"Increase of classic and nonclassic cardiovascular risk factors in patients with acromegaly","volume":"13","author":"Vilar L","year":"2007","journal-title":"Endocr Pract."},{"key":"ref62","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1530\/eje.0.1330430","article-title":"Effects of treatment with octreotide in acromegalic patients-a multicenter Italian study","volume":"133(4)","author":"Arosio M","year":"1995","journal-title":"Eur J Endocrinol."},{"issue":"11","key":"ref63","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1590\/S0100-879X2001001100009","article-title":"Risk factors for glucose intolerance in active acromegaly","volume":"34","author":"Kreze A","year":"2001","journal-title":"Braz J Med Biol Res."},{"key":"ref64","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1210\/jc.2007-1197","article-title":"Microalbuminuria and insulin sensitivity in patients with Gh-secreting pituitary tumor","volume":"93(3)","author":"Baldelli R","year":"2008","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"6","key":"ref65","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S1096-6374(02)00083-7","article-title":"Growth hormone receptor antagonist improves insulin resistance in acromegaly","volume":"12","author":"Rose DR","year":"2002","journal-title":"Growth Horm IGF Res."},{"issue":"9295","key":"ref66","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1016\/S0140-6736(01)06844-1","article-title":"Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist","volume":"358","author":"van der Lely AJ","year":"2001","journal-title":"Lancet."},{"issue":"4","key":"ref67","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1210\/jcem.87.4.8364","article-title":"Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist pegvisomant","volume":"87","author":"Sesmilo G","year":"2002","journal-title":"J Clin Endocrinol Metabolism."},{"issue":"3","key":"ref68","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1046\/j.1365-2265.2002.01460.x","article-title":"Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly","volume":"56","author":"Parkinson C","year":"2002","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"8","key":"ref69","first-page":"2730","article-title":"Mortality and cancer incidence in acromegaly: a retrospective cohort study","volume":"83","author":"Orme SM","year":"1998","journal-title":"J Clin Endocrinol Metabolism."}],"container-title":["Arquivos Brasileiros de Endocrinologia &amp; Metabologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/abem\/v52n9\/v52n9a04.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,17]],"date-time":"2019-05-17T16:24:25Z","timestamp":1558110265000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-27302008000900004&lng=pt&tlng=pt"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12]]},"references-count":69,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["S0004-27302008000900004"],"URL":"https:\/\/doi.org\/10.1590\/s0004-27302008000900004","relation":{},"ISSN":["0004-2730"],"issn-type":[{"value":"0004-2730","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12]]}}}